Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial - Concepedia

Concepedia

Publication | Open Access

Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial

DOI Full Paper Access

145

Citations

34

References

2020

Year

Shuhong Wang, Yusheng Lin, Xiao Xiong, Lu Wang, Yi Guo, Yuping Chen, Shaobin Chen, Geng Wang, Lin Peng, Hongcai Chen,

Clinical Cancer Research

Abstract

Low-dose metformin reprograms the TIME to an activated status and may be a suitable immune response modifier for further investigation in patients with ESCC.

References

	Year	Citations

Page 1